Dartmouth-Hitchcock logo
Summer Flowers In This Section
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (Cc-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Principal Investigator (?)
Chapman, M. Shane
Study Number
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis. Apremilast (CC-10004) is a new oral agent that is under clinical development for the treatment of inflammatory autoimmune disorders, such as psoriatic arthritis, psoriasis, rheumatoid arthritis, and Behçet disease. Etanercept is approved for the treatment of psoriasis; it is the most widely prescribed anti-tumor necrosis factor (TNF) for psoriasis. 
Phase (?)
Phase III
Sponsor (?)

Debra Rodgers
(603) 650-3160

Available at the following location(s)


View more details from ClinicalTrials.gov.